fashion -WSS

fashion

author：leisure time 2025-09-27 22:18:24 - browse：53

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： FDA struggles to regulate food additives, sometimes for decades

Wikipedia

WSS

New study raises questions about niacin and heart health

FDA warns medical device makers about rise in fabricated data

Will Ozempic

HHS leader on health, climate change and biopharma emissions

Senate committee scrutinizes Medicare Advantage brokers

2023 STAT Wunderkinds: get to know the winners

knowledge

fashion

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Congress may force more Covid

As demand for Covid shots wanes, Moderna seeks its next success

FDA struggles to regulate food additives, sometimes for decades

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Reporting on presidential health from Reagan to Trump and Biden

Trump demands the U.S. pay no more for drugs than other countries … again

The EU Joint Clinical Assessment needs to live up to its promise

Jerome Adams on the need for new antivirals for Covid

Medicare Advantage enrollment grows 7.1% to 33.4 million people

hotspot

Abridge raises $150m as clinical notes automation market heats up

How climate

New study raises questions about niacin and heart health

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

STAT Readout Newsletter: Today's biggest biotech updates

entertainment

knowledge

Wikipedia

knowledge